Moreson spray naz. doses. 50 mcg/dose in vial. 140 doses per pack. #1

Name:
Moreason spray naz. doses. 50 mcg/dose in vial. 140 doses per pack. #1
Description:
White or almost white suspension. The main active ingredient Mometasone Release form spray Dosage 50 mcg / dose in vial. 140 doses Pharmacological properties Pharmacodynamics Mometasone furoate is a synthetic corticosteroid for topical use. It has a pronounced anti-inflammatory effect. The local anti-inflammatory effect of mometasone furoate is manifested in doses at which systemic effects do not occur. Mometasone furoate inhibits the release of inflammatory mediators, significantly reduces the synthesis / release of leukotrienes from leukocytes in patients with allergic diseases. Mometasone furoate has demonstrated in cell culture a high potential (at least 10 times higher potency than other steroids, including beclomethasone dipropionate, betamethasone, hydrocortisone and dexamethasone) in inhibiting the synthesis/release of interleukins (IL-1, IL-6) and necrosis factor tumors (TNF-?); it also largely inhibits the formation of T-helper (Th2) IL-4 and IL-5. Mometasone furoate inhibits IL-5 production at least 6 times more than beclomethasone dipropionate and betamethasone. Pharmacokinetics With proper intranasal use, the systemic bioavailability of the drug is < 1%. At the same time, even with the use of high-tech methods, the drug is not detected in the blood serum. Mometasone suspension is very poorly absorbed in the gastrointestinal tract, and the small amount of mometasone suspension that can enter the gastrointestinal tract after nasal inhalation undergoes active primary metabolism even before excretion in the urine or bile. Indications for use Treatment of seasonal or perennial allergic rhinitis in adults and children aged 2 years and older; preventive treatment of moderate and severe allergic rhinitis in adults and children from 12 years of age (it is recommended to start 2-4 weeks before the expected start of the dusting season); treatment of symptoms of acute rhinosinusitis without signs of severe bacterial infection in adults and children over 12 years of age; treatment of nasal polyps and related symptoms, including nasal congestion and loss of smell, in patients 18 years of age or older. Dosage and administration Intranasally. Avoid contact with eyes. Before the first use, it is necessary to “calibrate” the spray by 10 presses of the dosing device until the spray begins to spray: Gently shake the bottle. Place your index and middle fingers on either side of the atomizer and your thumb under the vial. Do not pierce the nasal applicator. Point the sprayer away from you and then press down with your fingers 10 times until the spray begins to spray. If the nasal spray has not been used for 14 days or more, a re- "calibration" is necessary, which is carried out by pressing the dosing device 2 times until the spray appears. Treatment of seasonal or year-round allergic rhinitis: for adults (including the elderly) and adolescents over the age of 12, the recommended preventive and therapeutic dose of the drug is 2 injections (50 mcg each) in each nostril 1 time per day (total daily dose - 200 mcg). After achieving a therapeutic effect for maintenance therapy, it is advisable to reduce the dose to 1 injection in each nostril 1 time per day (total daily dose of 100 mcg). If the symptoms of the disease cannot be relieved by using the drug at the recommended therapeutic dose, the daily dose can be increased to the maximum: 4 injections in each nostril 1 time per day (total daily dose - 400 mcg). After easing the symptoms of the disease, a dose reduction is recommended. The clinical effect in some patients with seasonal allergic rhinitis is observed within 12 hours after the first dose. However, the full benefit of the treatment cannot be obtained in the first 48 hours, so the patient must continue regular use to achieve the full therapeutic effect. Treatment with Moreson may be started a few days before the start of the pollen season in patients with a history of moderate to severe seasonal allergic rhinitis. For children aged 2-11 years, the recommended therapeutic dose is 1 injection (50 mcg each) in each nostril 1 time per day (total daily dose - 100 mcg). Acute rhinosinusitis: for adults (including the elderly) and children aged 12 years and older, the recommended therapeutic dose is 2 injections (50 mcg) in each nostril 2 times a day (total daily dose - 400 mcg). Nasal polyps: For patients over the age of 18 years (including the elderly), the recommended dose is 2 injections (50 mcg each) in each nostril 1 time per day (total daily dose of 200 mcg). If after 5-6 weeks of treatment there is no improvement in the symptoms of the disease, the dose can be increased to two injections in each nasal passage 2 times a day (total daily dose - 400 mcg). The dose should be gradually reduced to a lower dose that provides effective control of the symptoms of the disease. If after 5-6 weeks of treatment there is no improvement in the symptoms of the disease, the patient's condition should be reviewed and alternative methods of treatment should be considered. How to use the nasal spray Gently shake the bottle and remove the dust cap. Clean your nose carefully. Close one nostril and place the nebulizer in the other nostril. Tilt your head slightly forward, holding the vial upright. Start inhaling gently or slowly through the nose and at the same time inject the spray into the nostril with a single press on the dosing device. Exhale through your mouth. Repeat step 4 to spray a second time in the same nostril, if applicable. Pull the nebulizer out of that nostril and exhale through your mouth. Repeat steps 3 and 6 for the second nostril. Wipe the sprayer thoroughly with a clean handkerchief or tissue after using the spray, put on the dust cap. Cleaning the nasal spray It is important to clean your nasal spray regularly, otherwise it will not work properly. Remove the dust cap and carefully remove the atomizer. Wash the atomizer and dust cap with warm water and then rinse under running water. Do not attempt to clean the dosing device with a needle or other sharp object, as this may damage the device and result in incorrect dosing of the medicinal substance. Dry the atomizer and dust cap in a warm place. Place the sprayer on the spray bottle and put on the dust cap. Re- "calibrate" by pressing the dispenser 2 times before use after cleaning. If you have used Moreson more than you were told, you must inform your doctor. Using steroids for a long time or in large amounts can sometimes affect some of your hormones. In children, it can affect growth and development. If the drug is missed, it is necessary to take this dose as soon as possible and continue the prescribed treatment regimen. Do not take a double dose to make up for a forgotten dose. Use during pregnancy and lactation Special studies of the effect of the drug in pregnant women have not been conducted. The drug should be prescribed only if the expected benefit to the mother outweighs the potential risk to the fetus or child. Infants whose mothers used corticosteroids during pregnancy should be carefully examined for possible hypofunction of the adrenal glands. Precautions Moreason should not be used in the presence of untreated local infection involving the nasal mucosa. Due to the fact that corticosteroids slow wound healing, such drugs should not be administered intranasally to patients who have recently undergone surgery or trauma to the nose until the wounds have completely healed. Morezon should be used with caution or not used at all for respiratory tuberculosis (including latent), untreated fungal, bacterial, systemic viral infections (including those caused by Herpes simplex with eye damage). The safety and efficacy of the drug in the treatment of unilateral polyps associated with cystic fibrosis or in the treatment of polyps that completely obstruct the nasal passage have not been established. Unusually located unilateral polyps, especially if they ulcerate or bleed, should be investigated. After 12 months of using mometasone furoate, there were no signs of atrophy of the nasal mucosa. However, patients who use Morezon for several months or longer should be periodically examined to identify possible changes in the nasal mucosa. In the event of the development of a local fungal infection of the nose or pharynx, it is necessary to cancel the drug and conduct special treatment. If irritation of the mucous membrane of the nose or pharynx persists for a long time, it may also be necessary to cancel the use of the drug. With prolonged treatment with Moreson, no signs of inhibition of the function of the hypothalamic-pituitary-adrenal system were observed. Patients switching to Moreson Nasal Spray after long-term treatment with systemic corticosteroids should be closely monitored. Discontinuation of systemic corticosteroids in these patients may lead to adrenal insufficiency, which may require the resumption of systemic corticosteroid therapy and other appropriate treatment. During the transition from treatment with systemic corticosteroids to treatment with Moreson, some patients may experience symptoms of corticosteroid withdrawal (eg, joint and/or muscle pain, fatigue, and depression) along with relief of nasal symptoms. Such patients need to be specifically convinced of the advisability of continuing treatment with Moreson. A change in therapy may also reveal allergic diseases (allergic conjunctiva, eczema, etc.) that have developed earlier and were masked by systemic corticosteroid therapy. Patients using corticosteroids may potentially have reduced immune reactivity and should be warned about the increased risk of infection in case of contact with patients with certain infectious diseases (eg, chicken pox, measles), as well as the need to consult a doctor if such contact occurs. Patients should be warned to seek immediate medical attention if signs or symptoms of a severe bacterial infection occur, such as fever, severe unilateral facial pain or toothache, orbital or periorbital swelling/edema, or worsening after initial improvement. Application in pediatrics. When conducting placebo-controlled clinical studies in children using Moreson at a daily dose of 100 mcg during the year, growth retardation was not observed. However, the long-term effects of intranasal/inhaled steroid use have not been conclusively investigated. The physician should carefully monitor the growth and development of children receiving long-term treatment with glucocorticosteroids. The safety and efficacy of Moreson have not been studied in the treatment of nasal polyps in children and adolescents under 18 years of age, symptoms of rhinosinusitis in children under 12 years of age, seasonal or perennial allergic rhinitis in children under 2 years of age. The use of high doses or long-term treatment with glucocorticosteroids can lead to systemic side effects, including growth retardation in children. In a study of 49 children who received Moreson 100 mg daily for 1 year, no decrease in growth rate was observed. The safety and efficacy of Moreson for the treatment of symptoms of acute rhinosinusitis in children under 12 years of age have not been studied. The use of the drug in young children should be carried out with the help of adults. Influence on the ability to drive vehicles and work with mechanisms The drug does not affect the ability to drive vehicles and work with mechanisms. Interaction with other drugs Combination therapy with loratadine was well tolerated by patients. However, there was no effect of the drug on the concentration of loratadine or its main metabolite in plasma. In these studies, mometasone furoate was not detected in plasma (with a sensitivity of the method of determination of 50 pg / ml). Contraindications Hypersensitivity to the components of the drug. Composition 1 dose of the drug contains: active substance: mometasone furoate - 50 mcg; excipients: avicel (microcrystalline cellulose treated with sodium carmellose), sodium citrate dihydrate, glycerin, citric acid monohydrate, polysorbate 80, benzalkonium chloride (in the form of a 50% solution), purified water. Overdose The drug has a low (< 1%) systemic bioavailability, so it is unlikely that in case of overdose, any measures will be required other than observation and subsequent administration of the drug at the recommended dose. Side effects During clinical studies with seasonal and year-round allergic rhinitis, the following undesirable effects associated with the use of Moreson were noted: headache (8%), nosebleeds (that is, obvious bleeding, as well as the release of bloody mucus or blood clots) (8%), pharyngitis (4%), burning sensation in the nose (2%), irritation (2%) and ulcerative changes (1%) of the nasal mucosa. The development of such adverse events is typical with the use of any nasal spray containing corticosteroids. Nosebleeds stopped spontaneously, were moderate, occurred slightly more often than with placebo (5%), but less often than with other intranasal corticosteroids that were studied and used as active controls (some of them had an incidence of nosebleeds up to 15 %). The incidence of other adverse events was comparable to that of placebo. In children, the incidence of adverse events, including nosebleeds (6%), headache (3%), nasal irritation (2%) and sneezing (2%), was comparable to placebo. After intranasal use of mometasone furoate, an immediate allergic reaction (for example: bronchospasm, dyspnea) can sometimes be observed. Very rarely, an anaphylactic reaction and angioedema have occurred. Isolated cases of taste and smell disorders have been reported. When using Moreson nasal spray as an adjuvant in the treatment of acute episodes of sinusitis, the following adverse events were noted, the frequency of which was compared with that of placebo: headache (2%), pharyngitis (1%), burning sensation in the nose (1%) and irritation of the nasal mucosa (1%). Nosebleeds were moderately severe, and the frequency of their occurrence with Moreson Spray was also compared with the frequency of nosebleeds with placebo (5% and 4%, respectively). In patients with nasal polyps, acute rhinosinusitis, the total number of the above events compared with placebo was compared with the use of Moreson Spray and was similar to the number that was detected in patients with allergic rhinitis. Very rarely, cases of perforation of the nasal septum or increased intraocular pressure have been observed with intranasal use of corticosteroids. Systemic effects may occur with the use of nasal corticosteroids, especially when administered at high doses and with long-term use. These effects are less likely than with oral corticosteroids and may differ between patients and between different corticosteroids. Potential systemic effects may include Cushing's syndrome, adrenal suppression, growth retardation in children and adolescents, cataracts, glaucoma, and, less commonly, psychiatric or behavioral disorders including psychomotor agitation, hyperactivity, sleep disturbance, anxiety, depression, or aggression (especially in children). Storage conditionsStore at a temperature not exceeding 25 °C. Keep out of the reach of children! Buy Moreson spray naz. doses. 50 mcg/dose in vial. 140 doses per pack. No. 1 Price for Moreson spray called. doses. 50 mcg/dose in vial. 140 doses per pack. No. 1 Instructions for use for Morezon spray naz. doses. 50 mcg/dose in a vial. 140 doses in a pack. #1